INTRODUCTION

With the advent of thin-strut designs and biocompatible polymers, second- or third-generation drug-eluting stents (DESs) have been demonstrated to have improved safety and efficacy compared with first-generation DESs [1-6]. Nonetheless, “routine follow-up coronary angiography (RFU CAG)” is still performed in some countries, including Korea, after second- or third-generation DES implantation [7]. RFU CAG is usually performed at 6 to 12 months after stent implantation for randomized stent trials or at the clinician’s discretion for the early detection and treatment of in-stent restenosis (ISR) or de novo lesions in high-risk patients. Several studies on the clinical impact of RFU CAG after implantation of bare-metal stents (BMSs) or first-generation DESs reported that RFU CAG did not affect long-term clinical outcome and caused more revascularization in angiographic follow-up group [8-16]. Despite the widespread adoption of second- and third-generation DESs, there is still a debate on the need for RFU CAG after second- or third-generation DES implantation in clinically stable patients. In the bare-metal stent era, routine follow-up coronary angiography (RFU CAG) was used to ensure stent patency. With the advent of drug-eluting stents (DESs) with better safety and efficacy profiles, RFU CAG has been performed less often. There are few data on the clinical impact of RFU CAG after second- or third-generation DES implantation in clinically stable patients with coronary artery disease; the aim of this study was to examine this issue.

Methods: We analyzed clinical outcomes retrospectively of 259 patients who were event-free at 12-month after stent implantation and did not undergo RFU CAG (clinical follow-up group) and 364 patients who were event-free prior to RFU CAG (angiographic follow-up group). Baseline characteristics were compared between the groups.

Results: The Kaplan-Meier estimated total survival and major adverse cardiac event (MACE)-free survival did not differ between the groups ($p = 0.100$ and $p = 0.461$, respectively). The cumulative MACE rate was also not different between the groups (hazard ratio, 0.85; 95% confidence interval, 0.35 to 2.02). In the angiographic follow-up group, 8.8% revascularization was seen at RFU CAG.

Conclusions: RFU CAG did not affect long-term clinical outcome after second- or third-generation DES implantation in clinically stable patients.

Keywords: Follow-up; Coronary angiography; Drug-eluting stents
are limited data on the clinical impact of RFU CAG after second- or third-generation DES implantation in clinically stable patients with coronary artery disease. Thus, we analyzed single-center data retrospectively and compared clinical outcomes between clinical follow-up and angiographic follow-up groups after implantation of second- or third-generation DESs. The clinical follow-up group was defined as those who were event-free at 12 months after stent implantation and did not undergo RFU CAG, and the angiographic follow-up group was defined as those who were event-free prior to RFU CAG.

METHODS

Patient selection
An observational study was conducted on patients receiving second- or third-generation DES at Hallym University Kangnam Sacred Heart Hospital, Hallym University Medical Center, Korea, between January 2007 and December 2012. From 920 initially screened patients, we excluded 271 who had experienced events (death, ischemic events, follow-up CAG due to symptoms or abnormal results in noninvasive tests, revascularization, or loss to follow-up) during the early term (the first 12 months after stent implantation in the clinical follow-up group and until RFU CAG in the angiographic follow-up group) and also excluded 26 further patients with late-term loss to follow-up. Overall, 623 patients were eligible to participate; of them 259 patients were event-free at 12 months after stent implantation and did not undergo RFU CAG (clinical follow-up group) and 364 patients were event-free prior to RFU CAG (angiographic follow-up group). RFU CAG was performed for randomized stent trials or at the clinician’s decisions. The stent types used were second- or third-generation DESs: Xience V, Xience Prime, Endeavor Sprint, Endeavor Resolute, Resolute Integrity, Promus Element, Nobori, and Biomatrix stents.

End point
The primary endpoint was major adverse cardiac events (MACEs). MACE included cardiovascular death, myocardial infarction (MI), ischemic heart failure requiring hospitalization (IHFRH), and revascularization. The definition of MI was a combination of changes in cardiac biomarkers and supporting information, derived from the clinical presentation, electrocardiographic changes, or the results of myocardial or coronary artery imaging. The definition of IHFRH was hospitalization, combined with clinical symptoms and signs of heart failure and no other noncardiac or cardiac etiology of heart failure, with the exception of ischemic heart disease, was demonstrable. Because the aim of this study was to evaluate the clinical impact of RFU CAG, which provides details not only on the stented segment but also on the entire vascular bed, we also included target vessel revascularization (TVM) and non-target vessel revascularization (NTVR) besides target lesion revascularization (TLR) in the revascularization of MACE. However, we did not include revascularization at RFU CAG in the revascularization of MACE because the main purpose of this study was to compare the long-term clinical outcome of the angiographic follow-up group with that of the clinical follow-up group who did not undergo RFU CAG. Causes of noncardiac death included cancer, bleeding, and infection.

Statistical analysis
The SPSS version 21.0 (IBM Co., Armonk, NY, USA) was used to analyze the results. All continuous variables are described as means ± SD. All categorical variables are described using absolute and relative frequency distributions. Comparisons between groups used unpaired t tests for continuous variables and chi-square tests for discrete variables. Survival curves were generated with the Kaplan-Meier method and compared using log-rank tests. We also used hazard ratios from Cox regression models to quantify relative risks of MACE. To identify independent predictors for MACE, multivariable logistic regression analysis was performed. A p < 0.05 was considered to indicate statistical significance.

RESULTS

Patients
The baseline characteristics of the two groups were not different, except older age and lower ejection fraction in the clinical follow-up group. The proportions of
DM, ST-segment-elevation myocardial infarction, and smoking patients were about 30%, 20%, and 50% in both groups. The proportion of patients with stent lengths longer than 30 mm was about 30% and proportion of patients with a left anterior descending coronary lesion was about 60% in both groups. The Endeavor stents were inserted more often in the angiographic follow-up group and Xience stents were used more often in the clinical follow-up group (Table 1). There was no difference in medication history, including antiplatelet agent and statin use, between the groups.

**Routine follow-up coronary angiography**
RFU CAG was performed in 364 patients and the mean follow-up duration of RFU CAG was 10.5 months. The revascularization rate at RFU CAG was 8.8%. More than half of revascularization was due to ISR (Table 2).

**Death and composite cardiac end point**
The mean clinical follow-up durations were 33 months in clinical follow-up group and 43 months in angiographic follow-up group. The Kaplan-Meier estimated total survival and MACE-free survival did not differ between the groups ($p = 0.100$ and $p = 0.461$, respectively) (Figs. 1 and 2). The cumulative MACE rate was also not different between the groups (hazard ratio, 0.85; 95% confidence interval).

---

**Table 1. Baseline clinical and coronary angiographic characteristics at baseline percutaneous coronary intervention**

| Characteristic          | Clinical follow-up (n = 259) | Angiographic follow-up (n = 364) | $p$ value |
|-------------------------|------------------------------|---------------------------------|-----------|
| Age, yr                 | 65 ± 10                      | 61 ± 10                         | < 0.001   |
| Sex (male)              | 169 (65.3)                   | 261 (71.7)                      | 0.092     |
| Background history      |                              |                                 |           |
| Hypertension            | 162 (62.5)                   | 194 (53.3)                      | 0.019     |
| Diabetes mellitus       | 80 (34.3)                    | 111 (30.5)                      | 0.277     |
| Smoker                  | 131 (50.4)                   | 191 (52.5)                      | 0.607     |
| STEMI                   | 54 (20.8)                    | 85 (23.4)                       | 0.445     |
| LVEF, %                 | 54 ± 14                      | 58 ± 11                         | 0.002     |
| Angiography             |                              |                                 |           |
| No. of stent (> 2)      | 26 (10.0)                    | 51 (14.0)                       | 0.133     |
| Stent length (> 30 mm)* | 75 (29.0)                    | 106 (29.1)                      | 0.976     |
| LAD lesion              | 162 (62.3)                   | 232 (63.7)                      | 0.715     |
| Stent types             |                              |                                 |           |
| Xience V, Prime         | 85 (32.8)                    | 73 (20.3)                       |           |
| Endeavor (Sprint, Resolute, R. Integrity) | 92 (35.5) | 181 (50.7) |           |
| Promus element          | 24 (9.3)                     | 29 (8.1)                        |           |
| Nobori                  | 54 (20.8)                    | 67 (18.8)                       |           |
| Biomatrix               | 4 (1.5)                      | 7 (2.0)                         |           |

Values are presented as mean ± SD or number (%).

STEMI, ST-segment-elevation myocardial infarction; LVEF, left ventricular ejection fraction; LAD, left anterior descending coronary.

aSingle or overlapped stent length more than 30 mm.

**Table 2. Characteristics of routine follow-up coronary angiography**

| Characteristic             | RFU CAG (n = 364)         |
|---------------------------|---------------------------|
| Follow-up, mo             | 10.5 ± 2.2                |
| PCI                       | 31 (8.5)                  |
| CABG                      | 1 (0.3)                   |
| ISR                       | 17 (4.6)                  |
| De novo progression       | 15 (4.1)                  |

Values are presented as mean ± SD or number (%).

RFU CAG, routine follow-up coronary angiography; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; ISR, in-stent restenosis.
The main finding of this study was that when a patient has not developed ischemic signs or symptoms at 12 months after second- or third-generation DES implantation, there is no need for a RFU angiography, with its added cost and procedural risk. Another issue is that RFU CAG causes a relatively high revascularization rate in patients with no ischemic signs or symptoms, via a phenomenon known as the “oculostenotic reflex” [14].

We performed this study to evaluate the clinical utility of mid-term follow-up CAG after second- or third-DES implantation. We assumed that when a patient was event-free at 12 months after second- or third-DES implantation, there would be no need for RFU angiography. This assumption was based on the findings of prior studies that nearly two-thirds of ischemic events after stent implantation occurred during the first 12 months [17-19]. Several studies on the clinical impact of RFU CAG after BMS or first-generation DES implantation showed that RFU CAG did not affect long-term clinical

**DISCUSSION**

The main finding of this study was that when a patient has not developed ischemic signs or symptoms at 12 months after second- or third-generation DES implantation, there is no need for a RFU angiography, with its added cost and procedural risk. Another issue is that RFU CAG causes a relatively high revascularization rate in patients with no ischemic signs or symptoms, via a phenomenon known as the “oculostenotic reflex” [14].

A multivariable logistic regression analysis revealed that the only significant predictors of MACE were hypertension and stent length more than 30 mm after adjusting for other factors (Table 4). Follow-up CAG was not a significant predictor of MACE.
outcomes and the follow-up angiography group suffered a twofold higher rate of revascularization, primarily due to revascularization at follow-up angiography [7-16]. These studies described that RFU angiography caused a high revascularization rate in patients who otherwise would not have undergone CAG. Revascularization at follow-up angiography was due to both TLR and TVR. However, with markedly lower rates of restenosis in the DES era, TLR tended to decrease and TVR had become a major proportion of revascularization cases [15]. One study reported that early treatment of de novo lesions as well as ISR lesions in the angiographic follow-up group was largely offset by revascularization performed later in the clinical follow-up group [15]. They described that late catch-up occurred in the clinical follow-up group and the revascularization rates were comparable between the angiographic follow-up and clinical follow-up groups by 3 years. Although there was no statistical significance, similar tendencies were observed in other studies [9-10]. Moreover, if we include the revascularizations at RFU CAG in MACE, as in other studies, then a tendency for initial high revascularization in the angiographic fol-

Table 3. Death and composite cardiac end point

| Characteristic          | Clinical follow-up (n = 259) | Angiographic follow-up (n = 364) | p value |
|-------------------------|------------------------------|---------------------------------|---------|
| Follow-up duration, mo  | 33 ± 16                      | 43 ± 18                         | < 0.001 |
| Noncardiac death\(a\)  | 6 (2.3)                      | 7 (1.9)                         | 0.610   |
| MACE                    | 8 (3.1)                      | 13 (3.5)                        | 0.849   |
| CV death                | 1                             | 2                               |         |
| MI (TL/TV/NTV)          | 4 (0/1/3)                    | 1 (0/1/0)                       |         |
| IHFRH                   | 0                             | 2                               |         |
| Revascularization (TL/TV/NTV) | 3 (1/1/1)                | 8 (2/3/3)                       |         |

Values are presented as mean ± SD or number (%).
MACE, major adverse cardiac event; CV, cardiovascular; MI, myocardial infarction; TL, target lesion; TV, target vessel; NTV, non-target vessel; IHFRH, ischemic heart failure requiring hospitalization.
\(a\)Noncardiac death were due to cancer, hemorrhage, and infection.

Table 4. Multivariable logistic regression analysis of major adverse cardiac events

| Variable           | Univariable OR (95% CI) | p value | Multivariable OR (95% CI) | p value |
|--------------------|--------------------------|---------|---------------------------|---------|
| Age                | 1.024 (0.976–1.074)      | 0.331   |                           |         |
| Sex                | 0.636 (0.165–2.452)      | 0.511   |                           |         |
| Hypertension       | 3.560 (1.088–11.650)     | 0.036   | 3.090 (1.023–9.333)       | 0.046   |
| Diabetes mellitus  | 1.328 (0.514–3.431)      | 0.557   |                           |         |
| Smoking            | 2.992 (0.827–10.824)     | 0.095   |                           |         |
| STEMI              | 0.439 (0.115–1.677)      | 0.228   |                           |         |
| LVGF               | 0.962 (0.928–0.997)      | 0.033   |                           |         |
| No. of stent       | 0.616 (0.284–1.333)      | 0.219   |                           |         |
| Stent length > 30 mm | 2.793 (0.919–8.490)    | 0.070   | 2.660 (1.104–6.412)       | 0.029   |
| LAD lesion         | 1.493 (0.533–4.185)      | 0.446   |                           |         |
| Stent types        | 1.007 (0.354–2.862)      | 0.595   |                           |         |
| Follow-up CAG      | 1.789 (0.649–4.932)      | 0.261   |                           |         |

OR, odds ratio; CI, confidence interval; STEMI, ST-segment-elevation myocardial infarction; LVGF, left ventricular ejection fraction; LAD, left anterior descending coronary; CAG, coronary angiography.
low-up group and late catch-up in the clinical follow-up group was also noted in our study. This early treatment effect of follow-up angiography may provide a rationale for performing follow-up angiography, but needs further research and a cost-effectiveness analysis. Considering the broad definition of revascularization in this study, including TLR, TVR, and NTVR, MACE rate of 3.1% and 3.5% in the groups in this study were lower than those in landmark studies: 5% to 7% [20-22]. However, the difference could also be attributable largely to the difference between the use of all-cause mortality in other studies versus cardiovascular mortality in this study. Because the MACE definition is heterogeneous and there is no consensus definition among the studies, caution is needed when comparing “MACE rates” between studies [23]. Another possible explanation for the lower MACE rate may be related to retrospective design of this study and the patients lost to follow-up may have undergone serious ischemic events and were lost to follow-up for that reason.

There are several limitations to this study. It was a single-center, retrospective study and the sample size was modest. Also, the two groups were inhomogeneous because this was not a prospective randomized study. However, we believe that our findings provide valuable insight on the role of RFU CAG after second- or third-generation DES implantation. In conclusion, we found that RFU CAG did not affect the long-term clinical outcome after second- or third-generation DES implantation in clinically stable patients.

**KEY MESSAGE**

1. Routine follow-up coronary angiography (CAG) did not affect long-term clinical outcome after second- or third-generation drug-eluting stent implantation in clinically stable patients.
2. Routine follow-up CAG may cause a revascularization in clinically stable patients who otherwise would not have undergone CAG, via a phenomenon known as the “oculostenotic reflex.”

**Conflict of interest**

No potential conflict of interest relevant to this article was reported.

**REFERENCES**

1. Stone GW, Midei M, Newman W, et al. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. JAMA 2008;299:1903-1913.
2. Stone GW, Midei M, Newman W, et al. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial. Circulation 2009;119:680-686.
3. Meredith IT, Worthley S, Whitbourn R, et al. Clinical and angiographic results with the next-generation resolute stent system: a prospective, multicenter, first-in-human trial. JACC Cardiovasc Interv 2009;2:977-985.
4. Mukherjee D, Moliterno DJ. Second-generation drug-eluting stents and the continuous need for rapidly available real-world data. JACC Cardiovasc Interv 2009;2:1236-1239.
5. Meredith IT, Worthley SG, Whitbourn R, et al. Long-term clinical outcomes with the next-generation resolute stent system: a report of the two-year follow-up from the RESOLVE clinical trial. EuroIntervention 2010;5:692-697.
6. Raber L, Magro M, Stefanini GG, et al. Very late coronary stent thrombosis of a newer-generation everolimus-eluting stent compared with early-generation drug-eluting stents: a prospective cohort study. Circulation 2012;125:1110-1121.
7. Uchida T, Popma J, Stone GW, et al. The clinical impact of routine angiographic follow-up in randomized trials of drug-eluting stents: a critical assessment of “oculostenotic” reintervention in patients with intermediate lesions. JACC Cardiovasc Interv 2010;3:403-411.
8. Rupprecht HJ, Espinola-Klein C, Erbel R, et al. Impact of routine angiographic follow-up after angioplasty. Am Heart J 1998;136(4 Pt 1):613-619.
9. Ruygrok PN, Melkert R, Morel MA, et al. Does angiography six months after coronary intervention influence management and outcome? Benestent II Investigators. J Am Coll Cardiol 1999;34:1507-1511.
10. ten Berg JM, Kelder JC, Suttert MJ, Verheugt FW, Thuis Plokker HW. Influence of planned six-month follow-up angiography on late outcome after percutaneous coronary intervention: a randomized study. J Am Coll Cardiol 2001;38:1061-1069.
11. Schuhlen H, Kastrati A, Mehilli J, et al. Restenosis detected by routine angiographic follow-up and late mortality after coronary stent placement. Am Heart J 2004;147:317-322.
12. Pinto DS, Stone GW, Ellis SG, et al. Impact of routine angiographic follow-up on the clinical benefits of paclitaxel-eluting stents: results from the TAXUS-IV trial. J Am Coll Cardiol 2006;48:32-36.
13. Shimada K, Kasaunuki H, Hagiwara N, Ogawa H, Yamauchi N. Routine coronary angiographic follow-up and subsequent revascularization in patients with acute myocardial infarction. Heart Vessels 2008;23:383-389.
14. Topol EJ, Nissen SE. Our preoccupation with coronary luminology: the dissociation between clinical and angiographic findings in ischemic heart disease. Circulation 1995;92:2333-2342.
15. Lansky AJ, Brar SS, Yaqub M, et al. Impact of routine angiographic follow-up after percutaneous coronary intervention with drug-eluting stents in the SPIRIT III randomized trial at three years. Am J Cardiol 2012;110:21-29.
16. Stone GW, Parise H, Witzenbichler B, et al. Selection criteria for drug-eluting versus bare-metal stents and the impact of routine angiographic follow-up: 2-year insights from the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial. J Am Coll Cardiol 2010;56:1597-1604.
17. Stone GW, Moses JW, Ellis SG, et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 2007;356:998-1008.
18. Stefanini GG, Kalesan B, Serruys PW, et al. Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial. Lancet 2011;378:1940-1948.
19. Camenzind E, Wijns W, Mauri L, et al. Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation: a randomised, multicentre, open-label, controlled trial. Lancet 2012;380:1496-1505.
20. Kandzari DE, Mauri L, Popma JJ, et al. Late-term clinical outcomes with zotarolimus- and sirolimus-eluting stents: 5-year follow-up of the ENDEAVOR III (a randomized controlled trial of the medtronic endeavor Drug [ABT-578] eluting coronary stent system versus the cypher sirolimus-eluting coronary stent system in de novo native coronary artery lesions). JACC Cardiovasc Interv 2011;4:543-550.
21. Stefanini GG, Byrne RA, Serruys PW, et al. Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials. Eur Heart J 2012;33:1214-1222.
22. Park TK, Song YB, Gwag HB, et al. Aspirin versus clopidogrel following dual antiplatelet therapy on the era of drug eluting stents. J Am Coll Cardiol 2014;63(12 Suppl):A1612.
23. Kip KE, Hollabaugh K, Marroquin OC, Williams DO. The problem with composite end points in cardiovascular studies: the story of major adverse cardiac events and percutaneous coronary intervention. J Am Coll Cardiol 2008;51:701-707.